|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.700 USD | +2.66% |
|
+4.65% | -89.31% |
| 25/06 | Jaguar Health to Seek European Regulatory Approval for Dog Diarrhea Treatment | MT |
| 11/06 | Jaguar Health Establishes First Site for Canalevia-CA1 Field Study | MT |
| Capitalization | 35.76L 30.58L 28.48L 26.49L 48.95L 31Cr 54.4L 3.41Cr 1.3Cr 14Cr 1.34Cr 1.31Cr 53Cr | P/E ratio 2025 * |
-0.27x | P/E ratio 2026 * | -0.86x |
|---|---|---|---|---|---|
| Enterprise value | -14.26L -12.19L -11.36L -10.56L -19.52L -12Cr -21.69L -1.36Cr -52.03L -5.73Cr -53.48L -52.38L -21Cr | EV / Sales 2025 * |
-0.11x | EV / Sales 2026 * | -0.08x |
| Free-Float |
81.66% | Yield 2025 * |
-
| Yield 2026 * | - |
More valuation ratios
* Estimated data
More news
Last Transcript: Jaguar Health, Inc.
More press releases
| 1 day | +2.66% | ||
| 1 week | +4.65% | ||
| Current month | +7.14% | ||
| 1 month | -29.50% | ||
| 3 months | -51.53% | ||
| 6 months | -89.20% | ||
| Current year | -89.31% |
| 1 week | 2.53 |  | 2.79 |
| 1 month | 2.43 | | 3.58 |
| Current year | 2.43 | | 33.25 |
| 1 year | 2.43 | | 110.75 |
| 3 years | 2.43 | | 40,387.45 |
| 5 years | 2.43 | | 10,00,000 |
| 10 years | 2.43 | | 10,00,000 |
| Manager | Title | Age | Since |
|---|---|---|---|
Lisa Conte
CEO | Chief Executive Officer | 66 | 06/06/2013 |
Carol Lizak
DFI | Director of Finance/CFO | 61 | 13/08/2019 |
| Chief Tech/Sci/R&D Officer | 63 | 01/05/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
Lisa Conte
BRD | Director/Board Member | 66 | 06/06/2013 |
James Bochnowski
CHM | Chairman | 81 | 01/06/2014 |
John Micek
BRD | Director/Board Member | 72 | 01/04/2016 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +2.66% | +4.65% | -97.35% | -99.99% | 35.76L | ||
| +0.30% | +1.58% | -16.38% | +145.07% | 71TCr | ||
| -0.50% | +0.57% | +4.68% | -10.78% | 38TCr | ||
| -1.31% | +1.67% | +13.02% | +26.23% | 34TCr | ||
| -3.64% | -2.74% | -55.22% | +8.38% | 31TCr | ||
| -2.36% | -1.23% | +0.78% | -21.80% | 26TCr | ||
| -3.00% | -1.93% | -3.83% | +16.05% | 24TCr | ||
| -1.66% | +1.10% | -14.76% | -6.40% | 22TCr | ||
| -0.79% | +3.00% | -34.75% | -10.94% | 21TCr | ||
| -1.70% | -1.00% | -10.75% | +19.56% | 16TCr | ||
| Average | -1.20% | +0.96% | -21.46% | +6.54% | 28.17TCr | |
| Weighted average by Cap. | -1.30% | +0.64% | -12.51% | +38.43% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 1.26Cr 1.07Cr 1Cr 93.02L 1.72Cr 107.73Cr 1.91Cr 12Cr 4.58Cr 50Cr 4.71Cr 4.61Cr 185.03Cr | 2.65Cr 2.27Cr 2.11Cr 1.97Cr 3.63Cr 227.78Cr 4.04Cr 25Cr 9.69Cr 106.65Cr 9.96Cr 9.75Cr 391.2Cr |
| Net income | -2.98Cr -2.55Cr -2.37Cr -2.21Cr -4.08Cr -255.61Cr -4.53Cr -28Cr -11Cr -119.68Cr -11Cr -11Cr -438.99Cr | -1.44Cr -1.23Cr -1.15Cr -1.07Cr -1.97Cr -123.56Cr -2.19Cr -14Cr -5.25Cr -58Cr -5.4Cr -5.29Cr -212.21Cr |
| Net Debt | -50.02L -42.77L -39.84L -37.06L -68.47L -43Cr -76.09L -4.77Cr -1.83Cr -20Cr -1.88Cr -1.84Cr -74Cr | -55.91L -47.81L -44.53L -41.42L -76.53L -48Cr -85.05L -5.34Cr -2.04Cr -22Cr -2.1Cr -2.05Cr -82Cr |
More financial data
* Estimated data
Employees
49
Sector
Pharmaceuticals
Calendar
| Date | Price | Change | Volume |
|---|---|---|---|
| 11/25/11 | 2.700 $ | +2.66% | 1,77,703 |
| 10/25/10 | 2.630 $ | 0.00% | 87,820 |
| 09/25/09 | 2.630 $ | +0.77% | 37,088 |
| 08/25/08 | 2.610 $ | +2.76% | 45,050 |
| 07/25/07 | 2.540 $ | -1.55% | 64,861 |
Delayed Quote Nasdaq, July 12, 2025 at 01:30 am IST
More quotes
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.700USD
Average target price
28.00USD
Spread / Average Target
+937.04%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- JAGX Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition